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aureus in patients undergoing hemodialysis: a
systematic review and meta-analysis
Cibele Grothe1*, Mônica Taminato1, Angélica Belasco1, Ricardo Sesso2 and Dulce Barbosa1Abstract
Background: This study was performed to evaluate the effectiveness of surveillance for screening and treatment of
patients with chronic kidney disease undergoing hemodialysis and colonized by Staphylococcus aureus.
Methods: A systematic review and meta-analysis were performed. The literature search involved the following
databases: the Cochrane Controlled Trials Register, Embase, LILACS, CINAHL, SciELO, and PubMed/Medline. The
descriptors were “Staphylococcus aureus”, “MRSA”, “MSSA”, “treatment”, “decolonization”, “nasal carrier”, “colonization”,
“chronic kidney disease”, “dialysis”, and “haemodialysis” or “hemodialysis”. Five randomized controlled trials that
exhibited agreement among reviewers as shown by a kappa value of >0.80 were included in the study; methodological
quality was evaluated using the STROBE statement. Patients who received various treatments (various treatments
group) or topical mupirocin (mupirocin group) were compared with those who received either no treatment or
placebo (control group). The outcomes were skin infection at the central venous catheter insertion site and bacteremia.
Results: In total, 2374 patients were included in the analysis, 626 (26.4%) of whom were nasal carriers of S. aureus. The
probability of S. aureus infection at the catheter site for hemodialysis was 87% lower in the mupirocin group than in
the control group (odds ratio [OR], 0.13; 95% confidence interval [CI], 0.05–0.34; p < 0.001). The risk of bacteremia was
82% lower in the mupirocin group than in the control group (OR, 0.18; 95% CI, 0.08–0.42; p < 0.001). No statistically
significant difference in bacteremia was observed between the various treatments group (excluding mupirocin) and
the control group (OR, 0.77; 95% CI, 0.51–1.15; p = 0.20).
Conclusions: Twenty-six percent of patients undergoing hemodialysis were nasal carriers of S. aureus. Of all treatments
evaluated, topical mupirocin was the most effective therapy for the reduction of S. aureus catheter site infection and
bacteremia in patients undergoing chronic hemodialysis.
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Staphylococcus aureus is the most frequently isolated
pathogen in hospitals worldwide. Approximately 20% of
healthy people are chronic carriers of S. aureus, 30% are
intermittent carriers, and 50% are not susceptible to car-
riage for unknown reasons [1].
Staphylococcus aureus infection has become endemic
in health care institutions worldwide. Up to 70% of in-
fections occur in such institutions. The reported half-life* Correspondence: cibelegrothe@hotmail.com
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unless otherwise stated.of colonization may reach 40 months in individuals who
do not receive treatment [2]. An estimated 2 million in-
dividuals are carriers of S. aureus based on prevalence
data in the Netherlands, while an estimated 53 million
are carriers in the United States [3].
In one study, the cloning results of S. aureus isolated
from blood were identical to those of S. aureus isolated
from nasal specimens in 82.2% of patients undergoing
hemodialysis (HD). These findings suggest that in these
patients, the organisms isolated from the blood origi-
nated from the nasal flora [1].
There are few reports on infection and colonization of
S. aureus because few countries conduct epidemiologicalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Grothe et al. BMC Nephrology 2014, 15:202 Page 2 of 9
http://www.biomedcentral.com/1471-2369/15/202surveillance of this microorganism. Information on
colonization can only be obtained when there is an ac-
tive search for carriers because colonization is asymp-
tomatic. After patients with chronic kidney disease
(CKD) undergoing conservative treatment are colonized
with S. aureus during hospitalization, these patients may
persist as carriers for a prolonged period of time, even
after hospital discharge. They may subsequently reintro-
duce the bacteria into the hospital during another hos-
pital admission [4].
The greatest risk of transmission occurs when the pa-
tient is not identified as a carrier. In a retrospective ana-
lysis that evaluated information from hospitalizations
during an 8-year period, a German hospital evaluated
the risk of acquiring S. aureus by patients who shared
the same hospital room with other colonized, but un-
identified, patients. The study found a 13% incidence of
infection by the same strain of S. aureus among colo-
nized patients [5]. Another study evaluated the preva-
lence of S. aureus on admission and found that 49% of
carrier patients would not have been identified without
screening on admission [1].
Infectious complications caused by S. aureus are com-
mon, and an increased frequency is being observed.
Such complications include bacteremia, endocarditis,
osteomyelitis, and metastatic abscesses [6]. The overall
mortality rate associated with S. aureus bacteremia
ranges from 11.9% to 46.5% [7].
Research performed in our institution demonstrated
that application of the topical antibiotic mupirocin at
the venous catheter insertion site significantly reduced
the risk of colonization and bloodstream infection with
S. aureus; moreover, the same result was observed in an-
other study conducted in Australia [8,9]. A systematic
literature review and meta-analysis published in 2011 in-
cluding 8 randomized controlled trials involving 3396
participants demonstrated that nasal decolonization of pa-
tients with S. aureus using mupirocin led to a significant
reduction in infections caused by this microorganism [10].
However, the emergence of strains resistant to multiple
drugs, including mupirocin, should be considered, such as
that demonstrated in a study from Spain [11].
Collection of surveillance cultures has been advocated
as a way to control the dissemination of multidrug-
resistant pathogens. Early detection of patients colo-
nized with multidrug-resistant microorganisms may
permit the effective establishment of measures to con-
trol cross-transmission [12].
Eradication of the carrier state of S. aureus includes
prevention of both infection and transmission. Several
eradication strategies have been evaluated, but these
studies differed significantly in their design.
To fill these knowledge gaps, we conducted a system-
atic review to evaluate the effectiveness of surveillancefor screening of S. aureus in patients with CKD and de-
termine the most effective intervention with which to
eradicate the transmission of this bacterium among pa-
tients with CKD undergoing HD.
Methods
This systematic review and meta-analysis follows the
steps proposed by the Cochrane Collaboration [13] and
is in accordance with PRISMA guidelines statement for
systematic review reporting [14]. The inclusion criterion
was S. aureus colonization in patients with CKD under-
going HD as the primary outcome. The exclusion cri-
teria were nonrandomized studies, letters, editorials, and
case reports; studies involving patients <18 years of age;
evaluation of S. aureus infection treatment outcomes
without evaluation of the effect of nasal colonization; and
no specification of the therapy administered to the
treatment group. The interventions compared in this
meta-analysis were surveillance for screening of nasal car-
riers of S. aureus, prophylactic treatment/decolonization
to control cross-transmission, and S. aureus infection
(bacteremia and skin infection at the catheter insertion
site) between treated and untreated patients undergoing
HD.
The following characteristics of each study were ex-
tracted: study design; total numbers of patients receiving
various treatments (various treatments group), mupirocin
(mupirocin group), and placebo or control (control group)
with corresponding rates of eradication; colonization by S.
aureus; duration of surveillance; number of patients with
skin infection at the catheter insertion site; and episodes
of bacteremia.
Study identification strategy
Relevant studies published from January 1989 to January
2014 were identified through a search of the following elec-
tronic databases: the Cochrane Library (including the
Cochrane Controlled Trials Register), Embase, LILACS,
SciELO, CINAHL, and Medline/PubMed. The principal
descriptors used in the search were “Staphylococcus
aureus”, “MRSA”, “MSSA”, “treatment”, “decolonization”,
“nasal carrier”, “colonization”,”chronic kidney disease”,
“dialysis”, and “haemodialysis” or “hemodialysis”.
Study selection
The studies were read by two independent reviewers (C.
G. and M.T.) to ascertain whether they fulfilled the in-
clusion criteria. The reviewers were not blinded. Each
reviewer evaluated the titles and abstracts of all identi-
fied studies and obtained complete photocopies of all
relevant articles. In cases of doubt or disagreement, a
third reviewer (D.A.B.) was solicited to issue an opinion
regarding whether the study should or should not be
included.
Grothe et al. BMC Nephrology 2014, 15:202 Page 3 of 9
http://www.biomedcentral.com/1471-2369/15/202Evaluation of methodological quality
Methodological quality was defined as confidence that
the study design and reporting were free of bias. Two in-
dependent reviewers used the recommendations of the
Cochrane framework and the STROBE statement
(STrengthening the Reporting of OBservational studies
in Epidemiology). Based on the STROBE recommenda-
tions [13], studies included in the meta-analysis were di-
vided into three categories: (A) >80% compliance with
the STROBE criteria, (B) 50% to 80% compliance with
the STROBE criteria, and (C) <50% compliance with the
STROBE criteria (Table 1).
Data extraction and statistical analysis
The studies were initially stratified according to their de-
sign. Based on these results, they were subsequently
stratified following the Cochrane methodology. Review
Manager 5 software, available from the Cochrane Col-
laboration, was used for statistical analysis. For dichot-
omous variables, the odds ratio (OR) with 95%
confidence interval (CI) was calculated using random-
effects and fixed-effects models. The Mantel–Haenszel
chi-squared test and the I2 test were used to calculate
heterogeneity [15].
Results
PRISMA flow chart in Figure 1 summarises the search
process. Initially, 143 articles were identified in the
PubMed/Medline database, 54 in SciELO, 32 in
Cochrane, 4 in LILACS, and 10 in Embase. Of the 243
total studies identified, 238 were excluded (36 were arti-
cles published and duplicated in different databases, 96
met the exclusion criteria, 84 did not present the princi-
pal result, 11 did not evaluate nasal colonization by S.
aureus, 7 did not report data on population control, and
4 did not report the duration of follow-up).
Thus, five studies were evaluated: a prospective double-
blind randomized controlled trial [16], three randomized
clinical trials [17-19], and one historical cohort [20]. All
studies were evaluated and classified as having a low risk
of bias and adequate methodological quality by the
Cochrane referential [13]. Randomization of the studies
included in this review was performed by a computer, and
concealment of the allocation was adequate.
These studies involved a total of 2,374 individuals
(1,177 patients in the intervention group and 1,197 inTable 1 Quality of clinical trials included in the present meta-
Concealment of
allocation
Blinded
investigator
Blinded
participant
Blind
asse
Adequate: 3 Yes: 3 Yes : 4 Yes :
Inadequate: 1 No : 1 No: 1 No: 1
Obscure: 1 Obscure: 1 Obscure: 0 Obscthe control group). Of these 2374 individuals, 626
(26.4%) were nasal carriers of S. aureus (see Additional
file 1).
Based on the STROBE recommendations [13], three
studies were placed in category A and two studies were
placed in category B. This meta-analysis did not include
studies in category C (<50% compliance with the criteria
established by STROBE) (Table 1).
Screening of S. aureus in nasal carriers
One study [20] provided strong evidence of a link be-
tween nasal colonization and bloodstream infection
caused by S. aureus. In that study, patients who devel-
oped infection were transiently recolonized by S. aureus
strains identical to the pretreatment colonized strains.
The strains were confirmed to be identical by molecular
typing and plasma DNA analysis.
Tracking methods that differed in frequency, location,
and quantity of samples among the studies were used to
identify S. aureus nasal carriers. One study [20] used
three nasal samples (one before the intervention, one 3–
5 days after the intervention, and one 10 days after the
intervention; samples were reevaluated 1, 3, and
12 months after decolonization). Two studies [17,18]
used three to five nasal samples at the beginning and
end of treatment. One study [16] measured IgG anti-
bodies for S. aureus type 5 and 8 capsular polysaccha-
rides for 2 years. Finally, one study [19] used nasal
samples at the beginning of the study and upon suspi-
cion of infection. Patients with three consecutive nega-
tive swabs were considered to be decolonized in most of
the studies.
Treatment/decolonization to control cross-transmission
Different interventions were evaluated, including topical
antimicrobial agents applied at the catheter insertion site
(2% mupirocin calcium ointment [17,19] and 10%
povidone-iodine solution [17,18]) or in the nasal region
(2% mupirocin calcium ointment [20]), bolus injection of
cefotaxime through a central venous catheter [CVC] [19],
and administration of an S. aureus vaccine containing type
5 and 8 capsular polysaccharides conjugated to nontoxic
recombinant proteins [16] (see Additional file 1).
Mupirocin was compared with placebo with respect to
eradication of colonization by S. aureus in three studies
[17,18,20]. In total, 494 patients were evaluated (246 inanalysis
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Figure 1 PRISMA flow diagram of systematic review inclusion and exclusion process.
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all 494 patients, 147 (30%) were nasal carriers of S. aur-
eus. The duration of treatment ranged from 140 to
570 days. Eradication of the nasal carrier state was suc-
cessful in approximately 98% (range, 96–100%) of pa-
tients receiving mupirocin after 30 to 90 days of
monitoring. One study [19] did not provide information
about nasal colonization by S. aureus in the control
group, and between-group comparison was therefore
not possible. However, eradication of nasal colonization
by S. aureus in the mupirocin group was 96% in that
study.
The lack of heterogeneity in the results (Q, 0.01; I2,
0.00; p = 0.92) indicates that the probability of S. aureus
nasal colonization in patients undergoing HD was 93%
lower in mupirocin-treated patients than in untreated or
placebo-treated patients [17,18] (OR, 0.05; 95% CI,
0.01–0.27) (Figure 2).Other treatments were encountered less frequently.
Administration of a povidone-iodine solution eradicated
nasal colonizationin 62% of carriers of S. aureus after
30 days of catheter placement [16], bolus catheter in-
jection of cefotaxime eradicated methicillin-resistant S.
aureus in 76% (n = 26/34) of patients [19], and adminis-
tration of a conjugate vaccine containing S. aureus type
5 and 8 capsular polysaccharides offered protection
against bacteremia by S. aureus in 90% of patients with
antibody levels of ≥80 pg/mL (the estimated minimum
level of protection) for up to approximately 40 weeks [16].
The acquisition of mupirocin resistance during treat-
ment was reported in one study. Boelaert et al. [20]
identified a strain of high-level mupirocin-resistant S.
aureus (minimum inhibitory concentration of >512 yg/
mL) after 19 months of mupirocin application among 29
strains isolated from patients colonized with S. aureus.
The adverse events attributable to mupirocin use were
Figure 2 Meta-analysis of mupirocin versus control: eradication of S. aureus nasal colonization in hemodialysis patients.
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[17,19,20]. The incidence of local reactions such as mal-
aise and myalgia was significantly higher in patients who
received the vaccine than in patients in the control
group, but they were mild or moderate and resolved
within 2 days [16].
Table 2 provides details regarding author, year of pub-
lication, study population, total number of patients in-
cluded, number of patients colonized with S. aureus (at
entry into the study), number of patients with skin infec-
tion at the dialysis catheter insertion site, and bacteremia
(see Additional file 1).
Prevention of skin infection at catheter insertion site and
S. aureus bacteremia in patients undergoing HD
Figure 3 shows that the probability of S. aureus skin in-
fection at the CVC insertion site for HD was 87% lower
in the mupirocin group than in the control group (OR,
0.13; 95% CI, 0.05–0.34; p = 0.000). There was no signifi-
cant heterogeneity among the studies (Q, 0.01; I2, 0.00;
p = 0.92).
As shown in Figure 4, the risk of bacteremia in pa-
tients undergoing HD using a CVC was 82% lower in
the mupirocin group than in the control group (OR,
0.18; 95% CI, 0.08–0.42. p < 0.0001). There was no sig-
nificant heterogeneity among the studies (Q, 0.01; I2,
0.00; p = 0.92).
Finally, no significant difference was observed in S.
aureus bacteremia in patients undergoing HD with
CVCs between the various treatments group (excluding
mupirocin) and the control group (OR, 0.77; 95% CI,
0.51–1.15; p = 0.198) (Figure 5).
Discussion
Staphylococcus aureus is the leading nosocomial patho-
gen worldwide [3]. Infection by S. aureus is associated
with high morbidity and mortality rates [21]. Effective
prevention strategies are essential because of the serious
sequelae of this infection. Prevention of S. aureusinfection has traditionally been focused on minimizing
cross infection. However, it has been repeatedly shown
that a high proportion of S. aureus infections originate
from the nasal flora [3].
Nasal carriage of S. aureus is a known risk factor for
subsequent infection in patients undergoing dialysis with
intravascular devices [3]. The rates of S. aureus nasal
colonization, skin infection at the exit of the CVC, and
bacteremia were studied in the present review, which in-
volved 2374 patients with CKD undergoing HD, 626
(26.4%) of whom were S. aureus nasal carriers.
Tracking methods for S. aureus nasal carrier identifica-
tion differed in frequency, location, and quantity of sam-
ples among the studies in this meta-analysis. Only two
studies [17,18] used the same screening strategy; therefore,
it is not possible to establish a strong, evidence-based, uni-
form recommendation regarding screening strategies.
In this review, mupirocin administration was the most
effective treatment for eradication of the S. aureus nasal
carrier state in the medium term (30–90 days); the esti-
mated probability of success using mupirocin compared
with no treatment was 93% (OR, 12.07; 95% CI, 0.01–
0.40). The total estimated decolonization rate using
other treatment methods was 76% from 4 to 40 weeks.
The efficacy of mupirocin decreased with a prolonged
follow-up period (>90 days). Moreover, a longer follow-
up period after a short treatment period resulted in an
increased risk of recolonization in other parts of the
body [5]. Although S. aureus is found in other parts of
the body beyond the nasal mucosa, its removal leads to
loss of colonization in other locations such as the hands
and skin; this indicates that the other body parts are in-
fected via the nasal colonization [7].
Boelaert et al. [20] provided evidence for a link be-
tween nasal colonization and bloodstream infection
caused by S. aureus. Patients who developed infections
were transiently recolonized by S. aureus strains identi-
cal to the strains isolated before treatment; the strains
were confirmed to be identical by molecular typing and
Table 2 Tracking and management of patients with chronic kidney disease colonized with S. aureus undergoing hemodialysis through a central venous
catheter
Author Year Design Patient (n) NCSA (n/%) Treatment Follow up Eradication SIIS (n) Bacteremia (n)
Treated
group
Control
group
Treated
group
Control
group
Treated
group
Control
group
Treated
group
Control
group
Treated
group
Control
group
Treated
group
Control
group
Hinefield16 2002 DBRCT 892 906 197 (22%) 200 (22%) Vaccine Placebo 17.5 months 17,2 months 86% NT NT 37 49
Sesso20 1998 RCT 69 67 28 (41%) 27 (40%) Mupirocin CIS 3x/s CIS 5 months
96% 5 24 2
11
Povidine iodine
Johnson22 2002 RCT 27 23 6 (22%) 6 (26%) Mupirocin CIS 3x/w Placebo 9 months 76% 0 5 1 5
Saxena23 2012 RCT 39 43 39 (100%) 43(100%) Catheter bolus
cefotaxime
Catheter bolus
heparin
12 months 100% 7 9 12 22
Boelaert30 1993 HC 150 15 80 (53%) 0 (0%) MUpirocin nasal3x\s No treatment 18 months 96% NT NT 4 18
Note: n. number of patients; % Percentage; NCSA nasal carrier of S. aureus; SIIS: skin infection at the central venous catheter insertion site; DBRCT: Double blind randomized controlled trial; RCT: randomized clinical
trial; HC: historical cohort; NT, not tested; CIS: catheter insertion site; 3x/w: three times per week.
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Figure 3 Meta-analysis of mupirocin versus control: S. aureus skin infection at catheter insertion site.
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strains in the mupirocin group (n = 16 patients) differed
from the original nasal strain. In contrast, four of the six
infectious strains in the placebo group (n = 18 patients)
were similar to the original nasal strain.
Despite improvements in HD techniques and CVC
care, infectious complications remain the leading cause
of death in patients undergoing HD [6]. Infection of the
CVC site is primarily responsible for death in more than
half of these patients [22].
A study involving 156 patients with CKD [6] demon-
strated that the risk of bloodstream infection was 1.3
times higher in patients with positive skin cultures at the
insertion site of the CVC for HD (relative risk, 1.29; 95%
CI, 0.83–1.98; p < 0.001) and that the risk of bacteremia
was 30% higher in patients with a positive culture at the
site of HD catheter insertion (relative risk, 1.29; 95% CI,
0.83–1.98; p < 0.001).
In this review, mupirocin applied to the catheter exit
site in S. aureus carriers was the most effective therapy
and reduced the likelihood of skin infection at the ca-
theter exit site by 87% in patients with CKD undergoing
HD compared with no treatment or placebo (OR, 00.13;Figure 4 Meta-analysis of mupirocin versus control: risk of S. aureus b95% CI, 0.05–0.34; p = 0.000). The risk of bacteremia in
these patients was 82% lower in the mupirocin group
than in the control group (OR, 00.18; 95% CI, 0.08–0.42;
p < 0.0001).
Boelaert et al. [20] reported that the incidence of S.
aureus bacteremia was four times lower after nasal
decolonization with mupirocin in patients with end-
stage renal disease than in the untreated group (0.024 vs.
0.097 per patient-year, p = 0.008). Johnson et al. [18]
conducted a clinical trial involving patients undergoing
HD and found a significantly lower incidence of
bacteremia-related bloodstream infection (7% vs. 35%,
p < 0.01) and longer survival duration (108 vs. 31 days,
p < 0.05) in patients treated with dermal mupirocin at the
CVC exit site three times a week than in untreated patients.
Sesso et al. [17] performed a prospective randomized study
and found that the proportion of patients with S. aureus
skin infection at the CVC insertion site was lower in the
mupirocin group than in the untreated group (4.3% vs.
23.9%, p = 0.001). In their study, S. aureus bacteremia was
observed in 17 patients: 2 in the mupirocin group (0.71
episodes per 1,000 patient-days) and 15 in the control
group (8.92 episodes per 1,000 patient-days; p < 0.001).acteremia.
Figure 5 Meta-analysis of diverse treatments versus control: risk of S. aureus bacteremia.
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periods is the emergence of mupirocin resistance. How-
ever, resistance has not been reported when treatment is
limited to mupirocin prophylaxis or healthy patients [3].
Three studies in the present meta-analysis evaluated
resistance to mupirocin, and only one showed resistance
associated with prolonged therapy. Notably, however,
the long-term effect on the development of resistance is
unknown because no studies have reported follow-up re-
sults of more than two Moreover, the techniques used
varied among studies, and mupirocin resistance was not
evaluated in most of them.
Recent studies of monitoring techniques, however,
have reported that mupirocin-resistant S. aureus infec-
tions related to the use of CVCs for HD have led to a re-
duction in drug efficacy in the long term as well as
emergence of resistance and recolonization by S. aureus.
These are major causes of morbidity and mortality
among these patients [10].
Alternatively, long-term studies have offered other
treatment options to achieve S. aureus elimination, such
as the proposed use of a conjugate vaccine that confers
only partial immunity against S. aureus bacteremia for
approximately 40 weeks in patients undergoing HD.
After this time period, the protective effect decreases as
the antibody levels began to decline [16].
One study showed that long-term cefotaxime blockade
of CVCs in patients with concurrent end-stage renal dis-
ease and nasal colonization by S. aureus undergoing HD
led to a significant overall reduction in the incidence of
bacteremia (1.47 vs. 3.44 episodes per 1000 catheter-
days, p < 0.001) and associated mortality (10.2% vs. 2.9%,
p < 0.05) compared with heparin-only blockade of CVCs.
This intervention is more effective against Gram-positive
cocci (p = 0.032), including methicillin-sensitive S. aureus
(p < 0.05). However, cefotaxime blockade provided no pro-
tection against methicillin-resistant S. aureus bacteremia
and showed antimicrobial resistance associated with pro-
longed use [19].There are some limitations in this meta-analysis. The
type and duration of HD access were not provided in most
studies. Thus, the differences in these potential risk factors
for S. aureus catheter-site infection and bacteremia be-
tween cases and controls could not be evaluated. Add-
itionally, the studies did not analyze S. aureus strains by
typing or DNA analysis to confirm the association be-
tween nasal colonization and infection. Finally, no studies
showed the results of a prolonged follow-up; therefore, it
was not possible to investigate mupirocin resistance. The
number of existing high-quality studies is too small to
compare the effects of interventions other than the use of
mupirocin. Local protocols and patient education inter-
ventions for the prevention of infection were not analyzed
in the present study.
Notably, a major obstacle faced by these patients is de-
layed diagnosis using conventional microbiological culture
methods. New screening methods such as real-time poly-
merase chain reaction allow for the detection of nasal
colonization in <2 hours. Identification of nasal carriers is
possible before infectious complications arise in this group
of patients. Combining these screening methods with a
short wait for effective treatment would allow for effective
treatment of this group of high-risk patients.
Conclusions
Colonization by S. aureus is common in patients under-
going chronic HD and occurred in 26.4% of such pa-
tients in this review. It is thus an important risk factor
for the development of infections in these patients.
In this meta-analysis, regular clearance of S. aureus
from the nose or use of a screening test to guide anti-
biotic therapy is recommended because the benefits of
mupirocin ointment are relatively short-lived.
Mupirocin ointment effectively reduces the risk of infec-
tion at the HD venous catheter insertion site as well as the
risk of catheter-related bacteremia. There are reports of
resistance to mupirocin, and this should be considered in
future studies with prolonged follow-up periods.
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long term. Given the large number of patients undergo-
ing HD and the importance of infectious complications
in these patients, eradication of the carrier state of S.
aureus seems justified. To date, topical mupirocin has
exhibited the most proven beneficial effects. However,
new alternatives should be further investigated in future
randomized clinical trials to guide decisions regarding
strategies for prevention of infections in patients under-
going chronic HD.
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